TY - JOUR
T1 - The phenotypic and genetic spectrum of patients with heterozygous mutations in cyclin M2 (CNNM2)
AU - Franken, Gijs A.C.
AU - Müller, Dominik
AU - Mignot, Cyril
AU - Keren, Boris
AU - Lévy, Jonathan
AU - Tabet, Anne Claude
AU - Germanaud, David
AU - Tejada, María Isabel
AU - Kroes, Hester Y.
AU - Nievelstein, Rutger A.J.
AU - Brimble, Elise
AU - Ruzhnikov, Maria
AU - Claverie-Martin, Felix
AU - Szczepańska, Maria
AU - Ćuk, Martin
AU - Latta, Femke
AU - Konrad, Martin
AU - Martínez-Cruz, Luis A.
AU - Bindels, René J.M.
AU - Hoenderop, Joost G.J.
AU - Schlingmann, Karl Peter
AU - de Baaij, Jeroen H.F.
N1 - Funding Information:
We thank Daan Viering and Dorien Lugtenberg for their help regarding the genetic analyses. This work was financially supported by ZonMW under the frame of EJPRD, the European Joint Programme on Rare Diseases (EJPRD2019‐40). In addition, this project has received funding from the European Union's Horizon 2020 research and innovation programme under the EJP RD COFUND‐EJP No. 825575. This contribution of Jeroen H. F. de Baaij and Joost G. J. Hoenderop was financially supported by a grant from the Netherlands Organization for Scientific Research: NWO Veni 016.186.012 and VICI 016.130.668, respectively. The contribution of coauthor F. Claverie‐Martin was supported by grant PI14/00760 cofinanced by the ISCIII‐Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund “Another way to build Europe.” The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Funding Information:
We thank Daan Viering and Dorien Lugtenberg for their help regarding the genetic analyses. This work was financially supported by ZonMW under the frame of EJPRD, the European Joint Programme on Rare Diseases (EJPRD2019-40). In addition, this project has received funding from the European Union's Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP No. 825575. This contribution of Jeroen H. F. de Baaij and Joost G. J. Hoenderop was financially supported by a grant from the Netherlands Organization for Scientific Research: NWO Veni 016.186.012 and VICI 016.130.668, respectively. The contribution of coauthor F. Claverie-Martin was supported by grant PI14/00760 cofinanced by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund “Another way to build Europe.” The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2021 The Authors. Human Mutation published by Wiley Periodicals LLC
PY - 2021/4
Y1 - 2021/4
N2 - Hypomagnesemia, seizures, and intellectual disability (HSMR) syndrome is a rare disorder caused by mutations in the cyclin M2 (CNNM2) gene. Due to the limited number of cases, extensive phenotype analyses of these patients have not been performed, hindering early recognition of patients. In this study, we established the largest cohort of HSMR to date, aiming to improve recognition and diagnosis of this complex disorder. Eleven novel variants in CNNM2 were identified in nine single sporadic cases and in two families with suspected HSMR syndrome. 25Mg2+ uptake assays demonstrated loss-of-function in seven out of nine variants in CNNM2. Interestingly, the pathogenic mutations resulted in decreased plasma membrane expression. The phenotype of those affected by pathogenic CNNM2 mutations was compared with five previously reported cases of HSMR. All patients suffered from hypomagnesemia (0.44–0.72 mmol/L), which could not be fully corrected by Mg2+ supplementation. The majority of patients (77%) experienced generalized seizures and exhibited mild to moderate intellectual disability and speech delay. Moreover, severe obesity was present in most patients (89%). Our data establish hypomagnesemia, seizures, intellectual disability, and obesity as hallmarks of HSMR syndrome. The assessment of these major features offers a straightforward tool for the clinical diagnosis of HSMR.
AB - Hypomagnesemia, seizures, and intellectual disability (HSMR) syndrome is a rare disorder caused by mutations in the cyclin M2 (CNNM2) gene. Due to the limited number of cases, extensive phenotype analyses of these patients have not been performed, hindering early recognition of patients. In this study, we established the largest cohort of HSMR to date, aiming to improve recognition and diagnosis of this complex disorder. Eleven novel variants in CNNM2 were identified in nine single sporadic cases and in two families with suspected HSMR syndrome. 25Mg2+ uptake assays demonstrated loss-of-function in seven out of nine variants in CNNM2. Interestingly, the pathogenic mutations resulted in decreased plasma membrane expression. The phenotype of those affected by pathogenic CNNM2 mutations was compared with five previously reported cases of HSMR. All patients suffered from hypomagnesemia (0.44–0.72 mmol/L), which could not be fully corrected by Mg2+ supplementation. The majority of patients (77%) experienced generalized seizures and exhibited mild to moderate intellectual disability and speech delay. Moreover, severe obesity was present in most patients (89%). Our data establish hypomagnesemia, seizures, intellectual disability, and obesity as hallmarks of HSMR syndrome. The assessment of these major features offers a straightforward tool for the clinical diagnosis of HSMR.
KW - CNNM2
KW - HSMR
KW - hypomagnesemia
KW - intellectual disability
KW - obesity
UR - http://www.scopus.com/inward/record.url?scp=85101823913&partnerID=8YFLogxK
U2 - 10.1002/humu.24182
DO - 10.1002/humu.24182
M3 - Article
C2 - 33600043
AN - SCOPUS:85101823913
SN - 1059-7794
VL - 42
SP - 473
EP - 486
JO - Human mutation
JF - Human mutation
IS - 4
ER -